Drug intelligence / Profile preview

tvs-CTL vaccine

Development stage: Phase 1
Lead developer: The University of Kansas Cancer Center
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

tvs-CTL is a therapeutic cancer vaccine developed by the University of Kansas Medical Center. It is an immunostimulant therapy designed to treat neoplasms, specifically targeting metastatic and unresectable melanoma. The approach involves enriching and activating autologous T-cells from a patient's own peripheral blood mononuclear cells, which are then redirected to recognize and attack tumor cells expressing the GD2 marker. The mechanism leverages immune system activation to enhance anti-tumor responses in patients with relapsed or refractory melanoma[1][3][4].

Other names: TVS-CTL Vaccine (University of Kansas Medical Center)Tvs-CTL metastatic melanoma vaccine

Targets

GD2-mimotope (GD2-derived peptide presented in MHC)

Beyond the preview

Go deeper on tvs-CTL vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tvs-CTL vaccine.

Explore the full profile